Board of Directors
Senior Advisor and Co-Founder
Mr. Dornbush co-founded and served as Iconic’s Chief Executive Officer from 2007 until 2014. Under his leadership, Iconic advanced ICON-1, the company’s lead asset, through non-clinical development and completed a successful Phase 1 study in wet AMD. Prior to the Company’s inception in 2003, Mr. Dornbush was President of Diem Investments, a private investment advisory firm. He continues to serve as Manager of Diem Bioventures, LLC, an investor in Iconic. Mr. Dornbush has served on numerous for profit and non-profit Boards including the Board of Directors of the National Park Foundation where he chaired the Foundation’s Investment Committee. Mr. Dornbush received his B.A. in English from The Colorado College and his JD from Boston University School of Law.
Mr. Foley has served as a member of Iconic Therapeutics’ Board of Directors since April 2014. Mr. Foley is a Managing Director with MPM Capital, a venture capital firm, which he joined in 1999. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr. Foley currently serves as a member of the board of directors of Rhythm, Chiasma, OSS, Selexys Pharmaceuticals, and Valeritas. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
William L. Greene, MD
Chief Executive Officer
K. Peter Hirth, PhD
Dr. Hirth has over 30 years of drug discovery and development expertise, and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, Afferent Pharmaceuticals, and Alios Biopharma. Most recently, Dr. Hirth served as co-founder and CEO of Plexxikon, Inc., where he built a novel, structure-guided drug discovery platform, which has brought several new chemical entities (NCEs) into the clinic such as Zelboraf®, which was approved by the FDA for metastatic melanoma together with a companion diagnostic. From 1991 to 2000, Dr. Hirth was with Sugen Inc., where he was instrumental in building the company from its inception, advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, Dr. Hirth was a Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval in 1989. Earlier in his career, Dr. Hirth was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. He received his PhD in molecular genetics from Heidelberg University, Germany.
Johan Kördel, PhD
Dr. Kördel is a Senior Partner with Lundbeckfond Ventures where he leads investments in the life sciences sector in the US and Europe. Previously, Dr. Kördel was co-founder and CEO of Sound Biotech ApS, and co-founder and Senior Vice President of Research and Business Development of Biovitrum (today part of SOBI). Previously, he worked at Pharmacia in leadership positions in research, early development, portfolio management, and business development. Dr. Kördel has co-founded other biotech companies and been appointed to numerous board positions both in private and public companies. He currently serves on Boards of Directors of Acacia Pharma, BoneSupport AB, Enterome SA, Ziarco, River Vision, and VHSquared. Dr. Kördel earned his PhD from Scripps Research Institute and Lund University, and completed his post-doctoral work at Harvard Medical School. He is an Associate Professor in Physical Chemistry at the University of Lund, Sweden.
Bruce Robertson, PhD
As a Managing Director at H.I.G. BioVentures, Dr. Robertson focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. He currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, Clarus Therapeutics, and Intersection Medical. Prior to joining H.I.G., Dr. Robertson served as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments, and previously was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. He started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Dr. Robertson is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. He holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.